JP2022529814A5 - - Google Patents
Info
- Publication number
- JP2022529814A5 JP2022529814A5 JP2021562854A JP2021562854A JP2022529814A5 JP 2022529814 A5 JP2022529814 A5 JP 2022529814A5 JP 2021562854 A JP2021562854 A JP 2021562854A JP 2021562854 A JP2021562854 A JP 2021562854A JP 2022529814 A5 JP2022529814 A5 JP 2022529814A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- composition according
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905711.6A GB201905711D0 (en) | 2019-04-24 | 2019-04-24 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
| GB1905711.6 | 2019-04-24 | ||
| PCT/EP2020/061083 WO2020216740A1 (en) | 2019-04-24 | 2020-04-21 | Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022529814A JP2022529814A (ja) | 2022-06-24 |
| JP2022529814A5 true JP2022529814A5 (https=) | 2023-04-28 |
| JP7543304B2 JP7543304B2 (ja) | 2024-09-02 |
Family
ID=66810218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562854A Active JP7543304B2 (ja) | 2019-04-24 | 2020-04-21 | 腎臓病の治療のための新規化合物及びその医薬組成物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12383544B2 (https=) |
| EP (1) | EP3958863B1 (https=) |
| JP (1) | JP7543304B2 (https=) |
| KR (1) | KR20220004111A (https=) |
| CN (1) | CN113727711A (https=) |
| AU (1) | AU2020263869A1 (https=) |
| BR (1) | BR112021021117A2 (https=) |
| CA (1) | CA3137445A1 (https=) |
| ES (1) | ES2982398T3 (https=) |
| GB (1) | GB201905711D0 (https=) |
| IL (1) | IL287392A (https=) |
| MA (1) | MA55752A (https=) |
| MX (1) | MX2021012544A (https=) |
| PH (1) | PH12021552680A1 (https=) |
| SG (1) | SG11202111739VA (https=) |
| WO (1) | WO2020216740A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025096453A1 (en) * | 2023-10-30 | 2025-05-08 | Vertex Pharmaceuticals Incorporated | Compounds for the treatment of kidney disease |
| WO2025121320A1 (ja) * | 2023-12-04 | 2025-06-12 | 国立大学法人山口大学 | 多発性嚢胞腎の予防又は治療剤 |
| TW202547458A (zh) * | 2024-03-26 | 2025-12-16 | 香港商禮邦醫藥（香港）有限公司 | 用於治療體染色體顯性多囊性腎病之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8362031B2 (en) * | 2004-08-20 | 2013-01-29 | University Of Kansas | Lonidamine analogues and treatment of polycystic kidney disease |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| EP2464354B1 (en) * | 2009-08-10 | 2015-04-01 | The Regents of The University of California | Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor |
| TWI704919B (zh) * | 2012-05-31 | 2020-09-21 | 日商大塚製藥股份有限公司 | 用於預防及/或治療多囊性腎臟病之藥物 |
| US10174012B2 (en) * | 2014-11-04 | 2019-01-08 | The University Of Kansas | LKB1-AMPK activators for therapeutic use in polycystic kidney disease |
| US10130622B2 (en) * | 2015-10-09 | 2018-11-20 | Abbvie S.Á.R.L. | Compounds for treatment of cystic fibrosis |
| AU2016333855A1 (en) | 2015-10-09 | 2018-04-26 | AbbVie S.à.r.l. | Substituted pyrazolo[3,4-b]pyridin-6-carboxylic acids and their use |
| RU2724345C2 (ru) | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| WO2018237174A2 (en) * | 2017-06-21 | 2018-12-27 | The Johns Hopkins University | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS |
-
2019
- 2019-04-24 GB GBGB1905711.6A patent/GB201905711D0/en not_active Ceased
-
2020
- 2020-04-21 CN CN202080030725.9A patent/CN113727711A/zh active Pending
- 2020-04-21 PH PH1/2021/552680A patent/PH12021552680A1/en unknown
- 2020-04-21 AU AU2020263869A patent/AU2020263869A1/en not_active Abandoned
- 2020-04-21 US US17/605,623 patent/US12383544B2/en active Active
- 2020-04-21 SG SG11202111739VA patent/SG11202111739VA/en unknown
- 2020-04-21 EP EP20721493.3A patent/EP3958863B1/en active Active
- 2020-04-21 ES ES20721493T patent/ES2982398T3/es active Active
- 2020-04-21 KR KR1020217038004A patent/KR20220004111A/ko not_active Withdrawn
- 2020-04-21 CA CA3137445A patent/CA3137445A1/en active Pending
- 2020-04-21 MX MX2021012544A patent/MX2021012544A/es unknown
- 2020-04-21 BR BR112021021117A patent/BR112021021117A2/pt not_active Application Discontinuation
- 2020-04-21 MA MA055752A patent/MA55752A/fr unknown
- 2020-04-21 JP JP2021562854A patent/JP7543304B2/ja active Active
- 2020-04-21 WO PCT/EP2020/061083 patent/WO2020216740A1/en not_active Ceased
-
2021
- 2021-10-19 IL IL287392A patent/IL287392A/en unknown